Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 10 Stomach Neoplasms 6 Colorectal Neoplasms 6 Biliary Tract Neoplasms 4 Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Gallbladder Neoplasms 2 Cholangiocarcinoma 2 Adenocarcinoma Of Esophagus 2 Sarcoma 1 Salivary Gland Neoplasms 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Muscle Invasive Bladder Cancer (MIBC) 1 Metastatic HER2-positive Breast Cancer 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 HER2-expressing Cancers 1 HER2-Positive Advanced Biliary Tract Cancer 1 Gastrointestinal Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Advanced Malignancies 1

Interventions

toripalimab 2 zanidatamab 1 tislelizumab 1 disitamab vedotin 1 Probiotics 1 Gemcitabine 1 Cisplatin 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Muscle Invasive Bladder Cancer (MIBC) × zanidatamab × Clear all

NCT07296705 2025-12-22

HARBOR

Fujian Medical University Union Hospital

Phase 2 Recruiting

Muscle Invasive Bladder Cancer (MIBC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡